Sandy Srinivas, MD, presented “Immunotherapy in Prostate Cancer” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Srinivas, Sandy “Immunotherapy in Prostate Cancer.” September 22, 2023. Accessed Aug 2024. https://grandroundsinurology.com/immunotherapy-in-prostate-cancer/
Immunotherapy in Prostate Cancer – Summary
Dr. Sandy Srinivas, MD, delves into the potential and challenges of using immunotherapy as a treatment modality for prostate cancer, emphasizing its role within the broader landscape of cancer immunology.
The unique immunological environment of prostate cancer has historically made it resistant to conventional immunotherapy approaches, yet recent advancements in immunotherapy for prostate cancer have been made. Dr. Srinivas highlights promising approaches, such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. She presents data from recent clinical trials demonstrating varying degrees of success with these treatments, particularly in metastatic and castration-resistant prostate cancer.
Srinivas also discusses integrating immunotherapy with other treatment modalities, including androgen deprivation therapy and radiation. This combination approach aims to enhance the efficacy of immunotherapy by modulating the tumor microenvironment and improving immune system activation.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practiced in this field now for more than 20 years . She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit . She serves as the Vice chair on the National Comphrehensive Cancer Center (NCCN) panel for prostate cancer and has coauthored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.
